Amneal Pharmaceuticals, Inc. (AMRX) financial statements and ratios from SEC XBRL: revenue $3.1B (TTM), net margin 2.4%, revenue growth 9.9% YoY, P/E 36.3. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (latest FY) | $3.02B |
| Revenue (TTM) | $3.1B |
| Net Margin | 2.4% |
| Operating Margin (TTM) | 14.6% |
| Net Debt / EBITDA | 5.4 |
| Revenue Growth (YoY) | 9.9% |
| EPS Growth (YoY) | 157.1% |
| FCF Growth (YoY) | -185.2% |
| P/E Ratio | 36.3 |
| EV / EBITDA | 17.9 |
| Price / Book | 173.02 |
| Price / Sales | 1.83 |
| FCF Yield | 2.2% |
| Altman Z-Score | 2.21 (grey) |
| Piotroski F-Score | 7/9 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| Sector P/E (Healthcare) | 21.7 |
AMRX overview · AMRX earnings · AMRX KPIs · AMRX documents · AMRX ownership · AMRX peers
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.